AAb to TAA Positive Total % Comment Reference p53 22
6
a
94
4
0
a
23.4
1
5
.
0
a
Promising diagnostic potential when incorporated in AAb assays to a panel of TAAs [23 ] p53 11 24 45.8 Association with higher risk for relapse. [24 ] p53 31 144 21.5 Correlation to higher stage, lymph node metastasis, negative ER, positive c-erbB-2 and worse survival. [25 ] p53 8 101 7.9 Correlated neither with p53 cytosolic assay nor with prognostic factors. [26 ] p53 22 220 10 Promising diagnostic potential when incorporated in AAb assays to a panel of TAAs [1 ] p53 296 2006 14.7 Summary of 15 studies (1979–1999). Frequency of AAbs: 2.8%–47.5%. Few studies showed association with high grade and poor survival. [27 ] MUC1 19
9
a
94
4
0
a
20.2
2
2
.
5
a
Promising diagnostic potential when incorporated in AAb assays to a panel of TAAs. [23 ] MUC1 2 24 8.3 No correlation to circulating mucin levels or stage of disease. [28 ] MUC1
3
6
b
1
1
c
1
4
0
b
6
1
c
2
5
.
7
b
1
8
.
0
c
Inverse correlation to extent of disease. Suggested role in protection against disease progression. [29 ] MUC1 20 100 20 Promising diagnostic potential when incorporated in AAb assays to a panel of TAAs. [1 ] HSP-27 219 579 37.8 Association with improved survival. [30 ] HSP-60 18
1
6
a
58
4
9
a
31
3
3
a
Promising diagnostic potential. [31 ] HSP-90 46 125 36.8 Correlation to extent of disease. Promising diagnostic potential. [32 ] HSP-90 135 214 63.1 Association with higher mortality rate. [33 ] HER2/neu 16
5
a
94
4
0
a
17.0
1
2
.
5
a
Promising diagnostic potential when incorporated in autoantibody assays against a panel of TAAs. [23 ] HER2/neu 11 20 55 HER2/neu oncoprotein elicits an immune response and may be used as a target for specific immunotherapy. [34 ] HER2/ne
u
b
12
9
d
3
e
107
4
4
d
6
3
e
11.2
2
0
.
4
d
4
.
8
e
Correlation to positive HER2/neu status in the primary tumor (
𝑃
=
.
0
3
). [35 ] HER2/ne
u
c
3 45 6.6 Incidence is lower in advanced-stage disease compared to early-stage disease. Suggested role in limiting disease progression. [36 ] HER2/neu 30 225 13 Promising diagnostic potential when incorporated in AAb assays to a panel of TAAs. [1 ] GIPC-1 17 22 77 Promising diagnostic potential. [37 ] c-myc 12
3
a
94
4
0
a
12.7
7
.
5
a
Promising diagnostic potential when incorporated in autoantibody assays against a panel of TAAs [23 ] c-myb 31 72 43 No correlation to c-myb status in the primary tumor. [38 ] NY-ESO-1/ LAGE-1 25
3
a
94
4
0
a
26.6
7
.
5
a
Promising diagnostic potential when incorporated in autoantibody assays against a panel of TAAs [23 ] BRCA1 8
1
a
94
4
0
a
8.5
2
.
5
a
No diagnostic potential, even if incorporated in autoantibody assays against a panel of TAAs [23 ] BRCA2 32
9
a
94
4
0
a
34.0
2
2
.
5
a
Promising diagnostic potential when incorporated in autoantibody assays against a panel of TAAs [23 ] Endostatin
2
4
b
2
5
c
3
6
b
5
9
c
6
6
.
6
b
4
2
.
4
c
Inverse correlation to extent of disease. No correlation to circulating levels of endostatin. Association with better prognosis in advanced-stage disease. [39 ] Lipophilin B 20
1
3
c
74
3
5
c
27.0
3
7
.
1
c
Correlation to extent of disease. Promising diagnostic potential. [40 ] Cyclin B1 3 7 42.8 Correlation to higher level of tumor cyclin B1 expression. Questionable diagnostic potential. [41 ] Cyclin D1 3 40 7.5 Questionable diagnostic potential [1 ] Fibulin 15 20 75 Promising diagnostic potential. [42 ] IGFBP2 21 142 15 Questionable diagnostic potential [1 ] IGFBP2 4 80 5 Questionable diagnostic potential [43 ] TOPO2α 8 115 7 Questionable diagnostic potential [1 ] Cathepsin D 5 100 5 Questionable diagnostic potential [1 ]
